Pharma Major Lupin announced today that its US subsidiary, Lupin Pharmaceuticals Inc. yesterday has launched its Amlodipine and Valsartan Tablets, 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg and 10 mg/320 mg, which are the AB rated generic equivalent of Novartis Pharmaceuticals Corporation's Exforge tablets 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg and 10 mg/320mg strengths.

Lupin had received final approval from the United States Food and Drug Administration (FDA) for the product yesterday. Lupin's Amlodipine and Valsartan Tablets is the combination tablet of Amlodipine, a dihydropyridine calcium channel blocker (DHP CCB) and Valsartan, an angiotensin II receptor blocker (ARB).

Shares of the company gained Rs 25.15, or 1.25%, to trade at Rs 2,032.20. The total volume of shares traded was 33,316 at the BSE (2.30 p.m., Wednesday).